Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for CFT8919, a metamorphic BiDA degradation agent licensed from U.S. firm C4 Therapeutics, Inc. (NASDAQ: CCCC). The study will focus on patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that carry epidermal growth factor receptor (EGFR) mutations.
Pre-clinical studies have demonstrated CFT8919’s activity in both in vivo and in vitro models of EGFR L858R-driven NSCLC, targeting a broad spectrum of drug-resistant mutations with intracranial activity, and showing potential to prevent or treat brain metastases in patients. In May 2023, Betta entered into a licensing agreement with C4T, securing exclusive rights to develop, manufacture, and commercialize the drug in Greater China, along with a sales commission, as detailed in the announcement.- Flcube.com
